179062-06-7

Basic information

• Product Name: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID
• Synonyms: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID;4-Fluoro-5-(trifluoromethyl)phenylene-1,2-diamine;4-Fluoro-5-(trifluoromethyl)benzene-1,2-diamine, 1,2-Diamino-4-fluoro-5-(trifluoromethyl)benzene;4-Fluoro-5-(trifluoroMethyl)benzene-1,2-diaMine;4,5-Diamino-2-fluorobenzotrifluoride97%;4-fluoro-5-(trifluoromethyl)-1,2-diaminobenzene
• CAS NO: 179062-06-7
• Molecular Formula: C₇H₆F₄N₂
• Molecular Weight: 194.1295528
• Mol File: 179062-06-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID(179062-06-7)
• EPA Substance Registry System: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID(179062-06-7)

Safety Data

• Hazardous Substances Data: 179062-06-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID is used as a reagent for the synthesis of orally efficacious benzimidazoles. These benzimidazoles act as melanin-concentrating hormone receptor 1 antagonists, which have potential applications in the treatment of various disorders related to the central nervous system, such as obesity and mood disorders.
In the synthesis process, 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID plays a crucial role in the formation of the benzimidazole structure, which is essential for the antagonistic activity against melanin-concentrating hormone receptor 1. Its unique properties, such as the presence of fluorine and trifluoromethyl groups, contribute to the overall stability and potency of the synthesized benzimidazoles, making them more effective as therapeutic agents.
Furthermore, the use of 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID in the synthesis of benzimidazoles allows for the development of new and improved drugs with better pharmacokinetic properties, such as increased bioavailability, longer half-life, and reduced side effects. This, in turn, can lead to more effective treatments for patients suffering from disorders related to the central nervous system.

Upstream product

• 143151-01-3 4-fluoro-2-nitro-5-(trifluoromethyl)acetanilide 
• 2357-47-3 4-Fluoro-3-trifluoromethylaniline 
• 2145-38-2 4-fluoro-3-(trifluoromethyl)acetanilide 
• 428871-73-2 5-fluoro-2-nitro-4-(trifluoromethyl)aniline 
• 179062-05-6 4-fluoro-2-nitro-5-trifluoromethyl-aniline 
• 1026828-94-3 N-(5-fluoro-2-nitro-4-trifluoromethyl-phenyl)-acetamide 
• 1026932-27-3 N-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide 

Downstream Products

• 846049-68-1 4-[(4-bromo-phenyl)-(5-fluoro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-70-5 1-(4-bromo-phenyl)-1-(5-fluoro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-6-aza-spiro[2.5]octane-6-carboxylic acid tert-butyl ester 
• 904283-21-2 2-[3-(1-benzyl-piperidin-4-yl)-3-(4-bromo-phenyl)-propyl]-5-fluoro-6-trifluoromethyl-1H-benzoimidazole 

Relevant articles and documents

2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, X, R1 and R11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.